Matches in Wikidata for { <http://www.wikidata.org/entity/Q66395849> ?p ?o ?g. }
Showing items 1 to 35 of
35
with 100 items per page.
- Q66395849 description "clinical trial" @default.
- Q66395849 description "ensayu clínicu" @default.
- Q66395849 description "klinisch onderzoek" @default.
- Q66395849 description "клінічне випробування" @default.
- Q66395849 name "Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy" @default.
- Q66395849 name "Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy" @default.
- Q66395849 type Item @default.
- Q66395849 label "Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy" @default.
- Q66395849 label "Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy" @default.
- Q66395849 prefLabel "Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy" @default.
- Q66395849 prefLabel "Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy" @default.
- Q66395849 P1050 Q66395849-87F39750-3E32-4E58-AAD8-3F61527AB7CB @default.
- Q66395849 P1132 Q66395849-C61148F7-4AA2-4B01-BD21-DBAF5471350F @default.
- Q66395849 P1476 Q66395849-7E07A466-9C46-4806-9150-7374BA4B0A7B @default.
- Q66395849 P17 Q66395849-3B6020DF-C44F-47D9-B641-3D60515B1ADE @default.
- Q66395849 P1813 Q66395849-89A80F9A-2CC2-49FC-A795-50FFD19FBA07 @default.
- Q66395849 P2899 Q66395849-65185C66-A81A-4321-9B49-6870EFEB6D84 @default.
- Q66395849 P3098 Q66395849-38141518-8252-4AC8-811F-0641ADC3FBF9 @default.
- Q66395849 P31 Q66395849-27E5EE86-F649-4132-A1E9-F5ECEFB3BAD9 @default.
- Q66395849 P580 Q66395849-62BF78BD-5712-4464-BA2B-DE81392A82F8 @default.
- Q66395849 P582 Q66395849-9DACC1AB-6D89-4B27-B7EF-5D48FDC768AF @default.
- Q66395849 P6099 Q66395849-54AB5DBD-2A4B-42A9-8B9A-1FB80E82B8CA @default.
- Q66395849 P8363 Q66395849-D53A689B-AED1-47E9-AF51-76DBEEB0D321 @default.
- Q66395849 P1050 Q12206 @default.
- Q66395849 P1132 "+604" @default.
- Q66395849 P1476 "6-Month, Multicenter, Randomized, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Non-Insulin Antihyperglycemic Drugs" @default.
- Q66395849 P17 Q865 @default.
- Q66395849 P1813 "EDITION AP" @default.
- Q66395849 P2899 "+18" @default.
- Q66395849 P3098 "NCT02855684" @default.
- Q66395849 P31 Q30612 @default.
- Q66395849 P580 "2016-08-24T00:00:00Z" @default.
- Q66395849 P582 "2018-08-06T00:00:00Z" @default.
- Q66395849 P6099 Q42824827 @default.
- Q66395849 P8363 Q78089383 @default.